Adial Pharmaceuticals

117 articles about Adial Pharmaceuticals

• Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

  4/22/2024

  Adial Pharmaceuticals, Inc. today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.

• Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04

  4/10/2024

  Adial Pharmaceuticals, Inc. announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD).

• Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

  4/2/2024

  Adial Pharmaceuticals, Inc. today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.

• Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

  3/2/2024

  Adial Pharmaceuticals, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term.

• Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

  2/28/2024

  Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.

• Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

  2/15/2024

  Adial Pharmaceuticals, Inc. announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024.

• Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

  2/13/2024

  Adial Pharmaceuticals, Inc. today announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder.

• Adial Announces Appointment of Tony Goodman as Chief Operating Officer

  1/18/2024

  Adial Pharmaceuticals, Inc. today announced the appointment of Tony Goodman as Chief Operating Officer.

• Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

  12/20/2023

  Adial Pharmaceuticals, Inc. announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement executed with Adovate for purchase of the assets and business of the Company’s wholly owned subsidiary, Purnovate, Inc.

• Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement - November 29, 2023

  11/29/2023

  Adial Pharmaceuticals, Inc. announced that it received notice from Nasdaq today that the Company has regained compliance with Nasdaq Listing Rule 5550, which requires listed companies to maintain stockholders' equity of at least $2,500,000.

• Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/14/2023

  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2023.

• Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

  10/31/2023

  Adial Pharmaceuticals, Inc. today announced that the Chief Medical Officer of Adial, Bankole Johnson, D.Sc., M.D., and Key Opinion Leaders will be presenting at The Annual International Society of Addiction Medicine Conference taking place November 2-4, 2023, in Marrakesh, Morocco.

• Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

  10/25/2023

  Adial Pharmaceuticals, Inc. recently hosted a virtual key opinion leader webinar with addiction experts Joseph Volpicelli, M.D., Ph.D., Executive Director and Founder of the Volpicelli Center; and Jonathan Hunt-Glassman, MBA, Chief Executive Officer and Co-founder of Oar Health, to discuss alcohol use disorder, the current treatment landscape, and the need for non-abstinence-based therapeutics.

• Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - October 24, 2023

  10/24/2023

  Adial Pharmaceuticals, Inc. announced that it has closed its previously announced private placement offering for the purchase and sale of an aggregate of 1,418,440 shares of its common stock, series A warrants to purchase up to 1,418,440 shares of common stock and series B warrants to purchase up to 1,418,440 shares of common stock, at a purchase price of $2.82 per share of common stock and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules.

• Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  10/20/2023

  Adial Pharmaceuticals, Inc. today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,418,440 shares of its common stock.

• Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

  10/19/2023

  Adial Pharmaceuticals, Inc. announced that it will be participating in the Fall Foliage MicroCap Rodeo Conference that will be held virtually Tuesday, October 24th through Friday, October 27th, 2023.

• Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

  10/19/2023

  Adial Pharmaceuticals, Inc. announces it has been awarded a key patent combining the use of the Company’s proprietary genetic diagnostic to detect select genotypes for genetically target treatment of alcohol use disorder and opioid use disorder with the Company’s lead investigational new drug product AD04.

• Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

  10/18/2023

  Adial Pharmaceuticals, Inc. announced that it has been awarded the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders industry by Frost & Sullivan, an American business consulting firm that offers market research and analysis, growth strategy consulting, and corporate training.

• Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

  9/28/2023

  Adial Pharmaceuticals, Inc. announced that on October 4, 2023, at 2:15 p.m. Eastern Time, it will be hosting a LinkedIn Live Key Opinion Leader webinar to discuss AUD, the current treatment landscape, and the need for non-abstinence-based therapeutics.

• Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.